Nanomix Inc., (Nanomix), a leading nanotechnology company focused on development of next generation Point of Care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, today announced that is has closed private financing for approximately $12 million.
The financing, received from a strategic corporate partner and existing investors, will fund the completion of development, registration clinical trials, and commercial launch of the Company's mobile diagnostic platform and initial assays.